AMGN vs RPRX · P/E 24, rev $10.05B vs P/E 15, rev $1.30B
Amgen Inc (AMGN) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the AMGN and RPRX stock pages for the full models.
Not investment advice.